Event Details

Abstract

Cancer is one of the leading causes of death worldwide and is well known for its complexity. Cancer cells within the same tumor or from different tumors are highly heterogeneous. Furthermore, stromal and immune cells within tumor microenvironment interact with cancer cells to play important roles in how tumor progress and respond to different treatments. Recent advances in single cell technologies, especially massively parallel single cell sequencing, have made it possible to analyze cancer cells and cells in its tumor microenvironment in parallel with unprecedented high resolution. We will summarize recent developments in single cell sequencing technologies and their applications in cancer research, and explain how insights generated from single cell sequencing can be used to develop novel diagnostic and therapeutic approaches to conquer cancer.

癌症是世界上主要的死亡原因之一,复杂性众所周知,来自不同肿瘤甚至同一肿瘤内的不同肿瘤细胞是高度异质的。并且肿瘤微环境中的基质细胞和免疫细胞与肿瘤细胞之间存在相互作用,在肿瘤进展和对不同治疗的反应中发挥重要作用。

现阶段单细胞技术发展迅猛,特别是大规模并行的单细胞测序为分析肿瘤细胞及肿瘤微环境中的细胞提供了前所未有的高分辨率。本次讲座将总结单细胞测序技术的最新发展及其在癌症研究中的应用,并探讨如何利用单细胞测序产生的结果指导新的诊断和治疗方法开发,从而战胜癌症。

Agenda

10:00 - 11:10
Single Cell Sequencing: A New Dimension in Cancer Diagnosis and Treatment
2020 年 12 月 23 日10:00—10:10 开场致辞10:10—10:55 Single Cell Sequenc...
2020 年 12 月 23 日

10:00—10:10 开场致辞
10:10—10:55 Single Cell Sequencing: A New Dimension in Cancer Diagnosis and Treatment
10:55—11:10 互动问答
view more

Speakers

  • 方南 (董事长,联合创始人,首席执行官 at 新格元生物科技有限公司)

    方南

    董事长,联合创始人,首席执行官 at 新格元生物科技有限公司

    http://www.singleronbio.com/

    方南博士简介:
    新格元董事长,联合创始人,首席执行官
    美国爱荷华大学 免疫学博士
    德国沃尔兹堡大学 MBA
    中国科学技术大学 生物学学士
    方南博士,一直在全球顶尖的生物公司从事产品研发、成果转化和管理的相关工作,拥有数十年的行业经验。曾任德国凯杰( QIAGEN)全球研发副总监及 “ Life Sciences Business Unit ” 管理委员会成员。负责NGS样品文库制备及单细胞应用方向产品开发,并直接参与公司策略。拥有在德国、美国和中国的多年团队管理经验及公司策略、并购及整合经验。曾带领团队共研发推出近30款科研和临检产品,拥有20余项专利及专利申请。
    曾任诺禾致源(Novogene)生物科技有限公司的副总经理,负责包括三代测序,HiC等科技服务新产品的开发与转化。是“南京市百名女企业家领航计划”、“2018年度创业江北高层次人才引进计划”、“创业南京高层次人才引进计划”,“苏州工业园区重大领军项目”和“江苏省双创人才“等荣誉称号和奖项的获得者。

    Nan Fang
    Chair of the Board
    Founder
    Chief Executive Officer
    Ph.D. Immunology, University of Iowa
    MBA, University of Wuerzburg
    B.S., Biology, University of Science and Technology of China
    Dr. Fang has over ten years of experience in product development, commercialization, team management, and corporate strategy in world-leading biotechnology companies in Germany, US, and China. Before co-founding Singleron, Dr. Fang was Deputy General Manager at Novogene, responsible for development of novel NGS service solutions. Prior to Novogene, she was Associate Director of Global R&D at QIAGEN, Germany, founding and leading the product development team of the Universal NGS Market Program. Dr. Fang was a member of Life Sciences Business Area Management Committee at QIAGEN and directly participated in decision-making process in the Business Area. At QIAGEN and Novogene, Dr. Fang and her team launched more than 30 products. She is inventor on over 20 patents and patent applications.
    Dr. Fang is also an Adjunct Professor at Anhui Medical University. Since 2018, Dr. Fang has been awarded multiple prices, including Forbes China Top 50 Women in Tech 2020; Jiangsu Province Entrepreneur of the Year 2019; one of 100 Leading Female Entrepreneurs in Nanjing; Nanjing Entrepreneurship Award; Technology Leadership of Suzhou BioBay; Technology Leadership of Suzhou City; and Innovation and Entrepreneurship Award of Jiangsu Province.

    view more

Community

Connect with 241 people attending this event